Related Experiment Video
Updated: May 1, 2026
Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles
Published on: September 18, 2018
Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles
Ruchi Dangi1, Pooja Hurkat, Ankit Jain
1Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Central University , Sagar, Madhya Pradesh , India.
Context:
Liver cancer is widespread liver malignancy in the world, for an estimated one million deaths annually.
Objective:
In present work, lactobionic acid conjugated PLGA nanoparticles (LDNPs) bearing 5-Fluorouracil (5-FU) were developed for targeted delivery to hepatocellular carcinoma.
Materials And Methods:
Lactobionic acid conjugated PLGA was used to prepare LDNPs using modified emulsion diffusion method.
Results:
They were characterised for particle morphology, particle size (below 150 nm), zeta potential and polydispersity index (PDI ∼0.35), entrapment efficiency (∼60.23%), and cumulative percent drug release.
Discussion:
LDNPs in ex-vivo cell line studies on human cancer cell line HepG2 exhibited significantly higher cytotoxicity compared to 5-FU and DNPs (unconjugated PLGA NPs) with growth inhibition 50% (GI50) of 66.7 µg/mL, 50.2 µg/mL and 35.5 µg/mL, respectively. In vivo studies exhibited higher drug concentration about 37.52 ± 0.68% in liver as compared to other organs and plasma.
Conclusion:
Thus, LDNPs showed high drug loading, specificity, biocompatibility and efficacy in treatment of liver cancer.
